Sofosbuvir is a hepatitis C (HCV) drug that has been recommended for treatment by the US FDA and EMA. HCV is a significant public health issue for middle-income countries, that are home to 73% of the 150 million people who are infected with HCV. Although HCV is curable, high drug prices make treatment inaccessible, leaving people at risk for liver cancer or liver failure.
I-MAK and our country partners have filed oppositions against Gilead/Pharmasset's patent applications because we believe that the technologies comprising these patent applications are known and therefore undeserving of a patent grant. We also believe that it is now time that People Living with HIV and HCV obtain affordable access to the drugs they need.
Summary of Legal Grounds of Opposition to Sofosbuvir Patents
Legal Documents for Opposition to Sofosbuvir (India)
Legal Documents for Opposition to Sofosbuvir (China)
I-MAK'S third party observation to the Chinese Patent Office against the prodrug application
MSF press release